Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of APX005M in Combination With Concurrent Chemoradiation as Neoadjuvant Therapy for Resectable Esophageal and Gastroesophageal Junction Cancers

NCT03165994 is registered in ClinicalTrials.gov with Apexigen America, Inc. as lead sponsor.

NCT NCT03165994
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03165994 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of APX005M in Combination With Concurrent Chemoradiation as Neoadjuvant Therapy for Resectable Esophageal and Gastroesophageal Junction Cancers
Lead sponsor
Apexigen America, Inc.
Phase
Phase 2
Overall status
Completed
Start date
October 6, 2017
Completion date
February 21, 2023
Enrollment
34 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal cancer, gastroesophageal cancer